#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-6	Gender	_
1-2	7-17	Dimorphism	_
1-3	18-20	of	_
1-4	21-26	Brain	_
1-5	27-33	Reward	_
1-6	34-40	System	_
1-7	41-48	Volumes	_
1-8	49-51	in	_
1-9	52-62	Alcoholism	http://maven.renci.org/NeuroBridge/neurobridge#StructuredAssessmentfortheGeneticsofAlcoholism
1-10	63-66	The	_
1-11	67-72	brain	_
1-12	73-75	's	_
1-13	76-82	reward	_
1-14	83-90	network	_
1-15	91-94	has	_
1-16	95-99	been	_
1-17	100-108	reported	_
1-18	109-111	to	_
1-19	112-114	be	_
1-20	115-122	smaller	_
1-21	123-125	in	_
1-22	126-135	alcoholic	_
1-23	136-139	men	_
1-24	140-148	compared	_
1-25	149-151	to	_
1-26	152-164	nonalcoholic	_
1-27	165-168	men	_
1-28	169-170	,	_
1-29	171-174	but	_
1-30	175-181	little	_
1-31	182-184	is	_
1-32	185-190	known	_
1-33	191-196	about	_
1-34	197-200	the	_
1-35	201-208	volumes	_
1-36	209-211	of	_
1-37	212-218	reward	_
1-38	219-226	regions	_
1-39	227-229	in	_
1-40	230-239	alcoholic	_
1-41	240-245	women	_
1-42	246-247	.	_

2-1	248-260	Morphometric	_
2-2	261-269	analyses	_
2-3	270-274	were	_
2-4	275-284	performed	_
2-5	285-287	on	_
2-6	288-296	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
2-7	297-306	resonance	_
2-8	307-312	brain	_
2-9	313-318	scans	_
2-10	319-321	of	_
2-11	322-324	60	_
2-12	325-334	long-term	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse
2-13	335-342	chronic	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse
2-14	343-353	alcoholics	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse
2-15	354-355	(	_
2-16	356-359	ALC	_
2-17	360-361	;	_
2-18	362-364	30	_
2-19	365-368	men	_
2-20	369-370	)	_
2-21	371-374	and	_
2-22	375-377	60	_
2-23	378-390	nonalcoholic	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
2-24	391-399	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
2-25	400-401	(	_
2-26	402-404	NC	_
2-27	405-406	;	_
2-28	407-409	29	_
2-29	410-413	men	_
2-30	414-415	)	_
2-31	416-417	.	_

3-1	418-420	We	_
3-2	421-428	derived	_
3-3	429-436	volumes	_
3-4	437-439	of	_
3-5	440-445	total	_
3-6	446-451	brain	_
3-7	452-453	,	_
3-8	454-457	and	_
3-9	458-466	cortical	_
3-10	467-470	and	_
3-11	471-482	subcortical	_
3-12	483-497	reward-related	_
3-13	498-508	structures	_
3-14	509-518	including	_
3-15	519-522	the	_
3-16	523-535	dorsolateral	_
3-17	536-546	prefrontal	_
3-18	547-548	(	_
3-19	549-554	DLPFC	_
3-20	555-556	)	_
3-21	557-558	,	_
3-22	559-572	orbitofrontal	_
3-23	573-574	,	_
3-24	575-578	and	_
3-25	579-588	cingulate	_
3-26	589-597	cortices	_
3-27	598-599	,	_
3-28	600-603	and	_
3-29	604-607	the	_
3-30	608-616	temporal	_
3-31	617-621	pole	_
3-32	622-623	,	_
3-33	624-630	insula	_
3-34	631-632	,	_
3-35	633-641	amygdala	_
3-36	642-643	,	_
3-37	644-655	hippocampus	_
3-38	656-657	,	_
3-39	658-665	nucleus	_
3-40	666-675	accumbens	_
3-41	676-681	septi	_
3-42	682-683	(	_
3-43	684-687	NAc	_
3-44	688-689	)	_
3-45	690-691	,	_
3-46	692-695	and	_
3-47	696-703	ventral	_
3-48	704-716	diencephalon	_
3-49	717-718	(	_
3-50	719-722	VDC	_
3-51	723-724	)	_
3-52	725-726	.	_

4-1	727-729	We	_
4-2	730-738	examined	_
4-3	739-742	the	_
4-4	743-756	relationships	_
4-5	757-759	of	_
4-6	760-763	the	_
4-7	764-774	volumetric	_
4-8	775-783	findings	_
4-9	784-786	to	_
4-10	787-795	drinking	_
4-11	796-803	history	_
4-12	804-805	.	_

5-1	806-814	Analyses	_
5-2	815-823	revealed	_
5-3	824-825	a	_
5-4	826-837	significant	_
5-5	838-844	gender	_
5-6	845-856	interaction	_
5-7	857-860	for	_
5-8	861-864	the	_
5-9	865-876	association	_
5-10	877-884	between	_
5-11	885-895	alcoholism	_
5-12	896-899	and	_
5-13	900-905	total	_
5-14	906-912	reward	_
5-15	913-920	network	_
5-16	921-928	volumes	_
5-17	929-930	,	_
5-18	931-935	with	_
5-19	936-939	ALC	_
5-20	940-943	men	_
5-21	944-950	having	_
5-22	951-958	smaller	_
5-23	959-965	reward	_
5-24	966-973	volumes	_
5-25	974-978	than	_
5-26	979-981	NC	_
5-27	982-985	men	_
5-28	986-989	and	_
5-29	990-993	ALC	_
5-30	994-999	women	_
5-31	1000-1006	having	_
5-32	1007-1013	larger	_
5-33	1014-1020	reward	_
5-34	1021-1028	volumes	_
5-35	1029-1033	than	_
5-36	1034-1036	NC	_
5-37	1037-1042	women	_
5-38	1043-1044	.	_

6-1	1045-1053	Analyses	_
6-2	1054-1056	of	_
6-3	1057-1058	a	_
6-4	1059-1065	priori	_
6-5	1066-1076	subregions	_
6-6	1077-1085	revealed	_
6-7	1086-1087	a	_
6-8	1088-1095	similar	_
6-9	1096-1103	pattern	_
6-10	1104-1106	of	_
6-11	1107-1113	reward	_
6-12	1114-1120	volume	_
6-13	1121-1132	differences	_
6-14	1133-1137	with	_
6-15	1138-1149	significant	_
6-16	1150-1156	gender	_
6-17	1157-1169	interactions	_
6-18	1170-1173	for	_
6-19	1174-1179	DLPFC	_
6-20	1180-1183	and	_
6-21	1184-1187	VDC	_
6-22	1188-1189	.	_

7-1	1190-1197	Overall	_
7-2	1198-1199	,	_
7-3	1200-1203	the	_
7-4	1204-1210	volume	_
7-5	1211-1213	of	_
7-6	1214-1217	the	_
7-7	1218-1226	cerebral	_
7-8	1227-1237	ventricles	_
7-9	1238-1240	in	_
7-10	1241-1244	ALC	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
7-11	1245-1257	participants	_
7-12	1258-1261	was	_
7-13	1262-1272	negatively	_
7-14	1273-1283	associated	_
7-15	1284-1288	with	_
7-16	1289-1297	duration	_
7-17	1298-1300	of	_
7-18	1301-1311	abstinence	_
7-19	1312-1313	,	_
7-20	1314-1324	suggesting	_
7-21	1325-1332	decline	_
7-22	1333-1335	in	_
7-23	1336-1343	atrophy	_
7-24	1344-1348	over	_
7-25	1349-1353	time	_
7-26	1354-1355	.	_

8-1	1356-1357	2	_
8-2	1358-1359	.	_

9-1	1360-1367	Methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
9-2	1368-1371	2.1	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
9-3	1372-1373	.	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod

10-1	1374-1382	Subjects	_
10-2	1383-1395	Participants	_
10-3	1396-1400	were	_
10-4	1401-1413	right-handed	_
10-5	1414-1415	(	_
10-6	1416-1426	handedness	_
10-7	1427-1429	as	_
10-8	1430-1438	assessed	_
10-9	1439-1441	in	_
10-10	1442-1443	)	_
10-11	1444-1447	men	_
10-12	1448-1451	and	_
10-13	1452-1457	women	_
10-14	1458-1462	from	_
10-15	1463-1466	the	_
10-16	1467-1473	Boston	_
10-17	1474-1478	area	_
10-18	1479-1480	.	_

11-1	1481-1484	The	_
11-2	1485-1490	study	_
11-3	1491-1499	included	_
11-4	1500-1502	60	_
11-5	1503-1512	abstinent	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent
11-6	1513-1522	long-term	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent
11-7	1523-1530	chronic	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent
11-8	1531-1541	alcoholics	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent
11-9	1542-1543	(	_
11-10	1544-1547	ALC	_
11-11	1548-1549	;	_
11-12	1550-1552	30	_
11-13	1553-1556	men	_
11-14	1557-1558	)	_
11-15	1559-1562	and	_
11-16	1563-1565	60	_
11-17	1566-1578	nonalcoholic	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
11-18	1579-1587	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
11-19	1588-1589	(	_
11-20	1590-1592	NC	_
11-21	1593-1594	;	_
11-22	1595-1597	29	_
11-23	1598-1601	men	_
11-24	1602-1603	)	_
11-25	1604-1605	(	_
11-26	1606-1611	Table	_
11-27	1612-1613	1	_
11-28	1614-1615	)	_
11-29	1616-1617	.	_

12-1	1618-1622	Nine	_
12-2	1623-1625	of	_
12-3	1626-1629	the	_
12-4	1630-1633	ALC	_
12-5	1634-1637	men	_
12-6	1638-1641	and	_
12-7	1642-1647	eight	_
12-8	1648-1650	of	_
12-9	1651-1654	the	_
12-10	1655-1657	NC	_
12-11	1658-1661	men	_
12-12	1662-1666	were	_
12-13	1667-1672	added	_
12-14	1673-1675	to	_
12-15	1676-1679	the	_
12-16	1680-1686	sample	_
12-17	1687-1689	of	_
12-18	1690-1693	men	_
12-19	1694-1697	who	_
12-20	1698-1701	had	_
12-21	1702-1714	participated	_
12-22	1715-1717	in	_
12-23	1718-1721	our	_
12-24	1722-1727	prior	_
12-25	1728-1736	research	_
12-26	1737-1738	.	_

13-1	1739-1742	The	_
13-2	1743-1746	ALC	_
13-3	1747-1750	men	_
13-4	1751-1754	and	_
13-5	1755-1760	women	_
13-6	1761-1765	were	_
13-7	1766-1774	selected	_
13-8	1775-1777	to	_
13-9	1778-1782	have	_
13-10	1783-1790	similar	_
13-11	1791-1799	drinking	_
13-12	1800-1807	history	_
13-13	1808-1816	profiles	_
13-14	1817-1818	.	_

14-1	1819-1832	Participation	_
14-2	1833-1836	was	_
14-3	1837-1846	solicited	_
14-4	1847-1851	from	_
14-5	1852-1861	newspaper	_
14-6	1862-1865	and	_
14-7	1866-1875	web-based	_
14-8	1876-1890	advertisements	_
14-9	1891-1894	and	_
14-10	1895-1899	from	_
14-11	1900-1906	Boston	_
14-12	1907-1917	University	_
14-13	1918-1925	Medical	_
14-14	1926-1932	Center	_
14-15	1933-1934	,	_
14-16	1935-1941	Boston	_
14-17	1942-1950	Veterans	_
14-18	1951-1958	Affairs	_
14-19	1959-1960	(	_
14-20	1961-1963	VA	_
14-21	1964-1965	)	_
14-22	1966-1976	Healthcare	_
14-23	1977-1983	System	_
14-24	1984-1985	,	_
14-25	1986-1989	and	_
14-26	1990-1992	VA	_
14-27	1993-2003	after-care	_
14-28	2004-2012	programs	_
14-29	2013-2014	.	_

15-1	2015-2018	The	_
15-2	2019-2032	Institutional	_
15-3	2033-2039	Review	_
15-4	2040-2046	Boards	_
15-5	2047-2049	of	_
15-6	2050-2053	the	_
15-7	2054-2067	participating	_
15-8	2068-2080	institutions	_
15-9	2081-2089	approved	_
15-10	2090-2094	this	_
15-11	2095-2100	study	_
15-12	2101-2102	.	_

16-1	2103-2111	Informed	_
16-2	2112-2119	consent	_
16-3	2120-2123	was	_
16-4	2124-2132	obtained	_
16-5	2133-2138	prior	_
16-6	2139-2141	to	_
16-7	2142-2160	neuropsychological	_
16-8	2161-2168	testing	_
16-9	2169-2172	and	_
16-10	2173-2181	scanning	_
16-11	2182-2183	.	_

17-1	2184-2196	Participants	_
17-2	2197-2201	were	_
17-3	2202-2212	reimbursed	_
17-4	2213-2216	for	_
17-5	2217-2221	time	_
17-6	2222-2225	and	_
17-7	2226-2232	travel	_
17-8	2233-2241	expenses	_
17-9	2242-2243	.	_

18-1	2244-2259	Neurobehavioral	_
18-2	2260-2263	and	_
18-3	2264-2275	psychiatric	_
18-4	2276-2287	evaluations	_
18-5	2288-2297	typically	_
18-6	2298-2306	required	_
18-7	2307-2311	from	_
18-8	2312-2315	six	_
18-9	2316-2318	to	_
18-10	2319-2323	nine	_
18-11	2324-2329	hours	_
18-12	2330-2334	over	_
18-13	2335-2338	two	_
18-14	2339-2341	or	_
18-15	2342-2346	more	_
18-16	2347-2351	days	_
18-17	2352-2353	.	_

19-1	2354-2366	Participants	_
19-2	2367-2370	had	_
19-3	2371-2379	frequent	_
19-4	2380-2386	breaks	_
19-5	2387-2389	as	_
19-6	2390-2396	needed	_
19-7	2397-2398	.	_

20-1	2399-2402	2.2	_
20-2	2403-2404	.	_

21-1	2405-2413	Clinical	_
21-2	2414-2424	Evaluation	_
21-3	2425-2428	and	_
21-4	2429-2447	Neuropsychological	_
21-5	2448-2458	Assessment	_
21-6	2459-2471	Participants	_
21-7	2472-2481	underwent	_
21-8	2482-2483	a	_
21-9	2484-2491	medical	_
21-10	2492-2499	history	_
21-11	2500-2509	interview	_
21-12	2510-2513	and	_
21-13	2514-2520	vision	_
21-14	2521-2528	testing	_
21-15	2529-2530	,	_
21-16	2531-2535	plus	_
21-17	2536-2537	a	_
21-18	2538-2544	series	_
21-19	2545-2547	of	_
21-20	2548-2562	questionnaires	_
21-21	2563-2564	(	_
21-22	2565-2569	e.g.	_
21-23	2570-2571	,	_
21-24	2572-2582	handedness	_
21-25	2583-2584	,	_
21-26	2585-2592	medical	_
21-27	2593-2600	history	_
21-28	2601-2602	,	_
21-29	2603-2610	alcohol	_
21-30	2611-2614	and	_
21-31	2615-2619	drug	_
21-32	2620-2623	use	_
21-33	2624-2625	)	_
21-34	2626-2628	to	_
21-35	2629-2635	ensure	_
21-36	2636-2640	they	_
21-37	2641-2644	met	_
21-38	2645-2654	inclusion	_
21-39	2655-2663	criteria	_
21-40	2664-2665	.	_

22-1	2666-2678	Participants	_
22-2	2679-2688	performed	_
22-3	2689-2690	a	_
22-4	2691-2699	computer	_
22-5	2700-2708	assisted	_
22-6	2709-2710	,	_
22-7	2711-2720	shortened	_
22-8	2721-2728	version	_
22-9	2729-2731	of	_
22-10	2732-2735	the	_
22-11	2736-2746	Diagnostic	http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies
22-12	2747-2756	Interview	http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies
22-13	2757-2765	Schedule	http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies
22-14	2766-2770	that	_
22-15	2771-2779	provides	_
22-16	2780-2788	lifetime	_
22-17	2789-2800	psychiatric	_
22-18	2801-2810	diagnoses	_
22-19	2811-2820	according	_
22-20	2821-2823	to	_
22-21	2824-2830	DSM-IV	_
22-22	2831-2839	criteria	_
22-23	2840-2841	.	_

23-1	2842-2854	Participants	_
23-2	2855-2859	were	_
23-3	2860-2868	excluded	_
23-4	2869-2873	from	_
23-5	2874-2881	further	_
23-6	2882-2895	participation	_
23-7	2896-2898	if	_
23-8	2899-2902	any	_
23-9	2903-2909	source	_
23-10	2910-2911	(	_
23-11	2912-2915	DIS	_
23-12	2916-2922	scores	_
23-13	2923-2924	,	_
23-14	2925-2933	hospital	_
23-15	2934-2941	records	_
23-16	2942-2943	,	_
23-17	2944-2953	referrals	_
23-18	2954-2955	,	_
23-19	2956-2958	or	_
23-20	2959-2967	personal	_
23-21	2968-2978	interviews	_
23-22	2979-2980	)	_
23-23	2981-2990	indicated	_
23-24	2991-2995	that	_
23-25	2996-3003	English	_
23-26	3004-3007	was	_
23-27	3008-3011	not	_
23-28	3012-3015	one	_
23-29	3016-3018	of	_
23-30	3019-3024	their	_
23-31	3025-3030	first	_
23-32	3031-3040	languages	_
23-33	3041-3042	,	_
23-34	3043-3045	or	_
23-35	3046-3048	if	_
23-36	3049-3053	they	_
23-37	3054-3057	had	_
23-38	3058-3061	any	_
23-39	3062-3064	of	_
23-40	3065-3068	the	_
23-41	3069-3078	following	_
23-42	3079-3080	:	_
23-43	3081-3090	corrected	_
23-44	3091-3097	visual	_
23-45	3098-3104	acuity	_
23-46	3105-3110	worse	_
23-47	3111-3115	than	_
23-48	3116-3121	20/50	_
23-49	3122-3124	in	_
23-50	3125-3129	both	_
23-51	3130-3134	eyes	_
23-52	3135-3136	;	_
23-53	3137-3146	Korsakoff	_
23-54	3147-3149	's	_
23-55	3150-3158	syndrome	_
23-56	3159-3160	;	_
23-57	3161-3164	HIV	_
23-58	3165-3166	;	_
23-59	3167-3176	cirrhosis	_
23-60	3177-3178	;	_
23-61	3179-3184	major	_
23-62	3185-3189	head	_
23-63	3190-3196	injury	_
23-64	3197-3201	with	_
23-65	3202-3206	loss	_
23-66	3207-3209	of	_
23-67	3210-3223	consciousness	_
23-68	3224-3231	greater	_
23-69	3232-3236	than	_
23-70	3237-3239	30	_
23-71	3240-3247	minutes	_
23-72	3248-3257	unrelated	_
23-73	3258-3260	to	_
23-74	3261-3271	alcoholism	_
23-75	3272-3273	;	_
23-76	3274-3280	stroke	_
23-77	3281-3282	;	_
23-78	3283-3291	epilepsy	_
23-79	3292-3294	or	_
23-80	3295-3303	seizures	_
23-81	3304-3313	unrelated	_
23-82	3314-3316	to	_
23-83	3317-3327	alcoholism	_
23-84	3328-3329	;	_
23-85	3330-3343	schizophrenia	_
23-86	3344-3345	;	_
23-87	3346-3354	Hamilton	http://maven.renci.org/NeuroBridge/neurobridge#DepressionRatingScale
23-88	3355-3361	Rating	http://maven.renci.org/NeuroBridge/neurobridge#DepressionRatingScale
23-89	3362-3367	Scale	http://maven.renci.org/NeuroBridge/neurobridge#DepressionRatingScale
23-90	3368-3371	for	http://maven.renci.org/NeuroBridge/neurobridge#DepressionRatingScale
23-91	3372-3382	Depression	http://maven.renci.org/NeuroBridge/neurobridge#DepressionRatingScale
23-92	3383-3384	(	http://maven.renci.org/NeuroBridge/neurobridge#DepressionRatingScale
23-93	3385-3389	HRSD	http://maven.renci.org/NeuroBridge/neurobridge#DepressionRatingScale
23-94	3390-3391	)	http://maven.renci.org/NeuroBridge/neurobridge#DepressionRatingScale
23-95	3392-3397	score	_
23-96	3398-3402	over	_
23-97	3403-3405	16	_
23-98	3406-3407	;	_
23-99	3408-3425	electroconvulsive	_
23-100	3426-3433	therapy	_
23-101	3434-3435	;	_
23-102	3436-3443	history	_
23-103	3444-3446	of	_
23-104	3447-3451	drug	_
23-105	3452-3455	use	_
23-106	3456-3460	once	_
23-107	3461-3464	per	_
23-108	3465-3469	week	_
23-109	3470-3472	or	_
23-110	3473-3477	more	_
23-111	3478-3484	within	_
23-112	3485-3488	the	_
23-113	3489-3493	past	_
23-114	3494-3498	four	_
23-115	3499-3504	years	_
23-116	3505-3506	(	_
23-117	3507-3513	except	_
23-118	3514-3517	for	_
23-119	3518-3521	one	_
23-120	3522-3525	ALC	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
23-121	3526-3531	woman	_
23-122	3532-3535	who	_
23-123	3536-3539	had	_
23-124	3540-3543	not	_
23-125	3544-3550	smoked	_
23-126	3551-3560	marijuana	_
23-127	3561-3567	within	_
23-128	3568-3571	the	_
23-129	3572-3576	past	_
23-130	3577-3580	six	_
23-131	3581-3587	months	_
23-132	3588-3589	,	_
23-133	3590-3593	and	_
23-134	3594-3597	one	_
23-135	3598-3601	ALC	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
23-136	3602-3605	man	_
23-137	3606-3609	who	_
23-138	3610-3613	had	_
23-139	3614-3617	not	_
23-140	3618-3622	used	_
23-141	3623-3630	cocaine	_
23-142	3631-3637	within	_
23-143	3638-3641	the	_
23-144	3642-3646	past	_
23-145	3647-3652	eight	_
23-146	3653-3659	months	_
23-147	3660-3661	)	_
23-148	3662-3663	.	_

24-1	3664-3665	A	_
24-2	3666-3672	number	_
24-3	3673-3675	of	_
24-4	3676-3688	participants	_
24-5	3689-3693	were	_
24-6	3694-3700	taking	_
24-7	3701-3712	medications	_
24-8	3713-3716	for	_
24-9	3717-3718	a	_
24-10	3719-3726	variety	_
24-11	3727-3729	of	_
24-12	3730-3740	conditions	_
24-13	3741-3742	,	_
24-14	3743-3746	had	_
24-15	3747-3751	used	_
24-16	3752-3757	drugs	_
24-17	3758-3765	earlier	_
24-18	3766-3770	than	_
24-19	3771-3775	four	_
24-20	3776-3781	years	_
24-21	3782-3788	before	_
24-22	3789-3799	enrollment	_
24-23	3800-3801	,	_
24-24	3802-3804	or	_
24-25	3805-3808	had	_
24-26	3809-3810	a	_
24-27	3811-3822	potentially	_
24-28	3823-3834	confounding	_
24-29	3835-3842	medical	_
24-30	3843-3850	history	_
24-31	3851-3852	.	_

25-1	3853-3862	Therefore	_
25-2	3863-3864	,	_
25-3	3865-3867	in	_
25-4	3868-3876	analyses	_
25-5	3877-3879	of	_
25-6	3880-3883	the	_
25-7	3884-3891	results	_
25-8	3892-3893	,	_
25-9	3894-3895	a	_
25-10	3896-3904	subgroup	_
25-11	3905-3907	of	_
25-12	3908-3910	85	_
25-13	3911-3923	participants	_
25-14	3924-3925	(	_
25-15	3926-3928	31	_
25-16	3929-3932	ALC	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
25-17	3933-3934	;	_
25-18	3935-3937	54	_
25-19	3938-3940	NC	_
25-20	3941-3942	)	_
25-21	3943-3946	was	_
25-22	3947-3954	created	_
25-23	3955-3965	consisting	_
25-24	3966-3968	of	_
25-25	3969-3970	“	_
25-26	3971-3983	unconfounded	_
25-27	3984-3985	”	_
25-28	3986-3998	participants	_
25-29	3999-4002	who	_
25-30	4003-4007	were	_
25-31	4008-4011	not	_
25-32	4012-4021	currently	_
25-33	4022-4028	taking	_
25-34	4029-4041	psychotropic	_
25-35	4042-4053	medications	_
25-36	4054-4055	,	_
25-37	4056-4059	and	_
25-38	4060-4068	reported	_
25-39	4069-4074	never	_
25-40	4075-4080	using	_
25-41	4081-4088	illicit	_
25-42	4089-4094	drugs	_
25-43	4095-4099	more	_
25-44	4100-4104	than	_
25-45	4105-4109	once	_
25-46	4110-4111	a	_
25-47	4112-4116	week	_
25-48	4117-4118	.	_

26-1	4119-4131	Additionally	_
26-2	4132-4133	,	_
26-3	4134-4138	that	_
26-4	4139-4147	subgroup	_
26-5	4148-4151	was	_
26-6	4152-4162	restricted	_
26-7	4163-4165	to	_
26-8	4166-4177	individuals	_
26-9	4178-4181	for	_
26-10	4182-4186	whom	_
26-11	4187-4189	no	_
26-12	4190-4196	source	_
26-13	4197-4206	indicated	_
26-14	4207-4208	:	_
26-15	4209-4218	hepatitis	_
26-16	4219-4220	;	_
26-17	4221-4223	an	_
26-18	4224-4228	HRSD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
26-19	4229-4234	score	_
26-20	4235-4239	over	_
26-21	4240-4242	13	_
26-22	4243-4244	;	_
26-23	4245-4247	or	_
26-24	4248-4251	any	_
26-25	4252-4254	of	_
26-26	4255-4258	the	_
26-27	4259-4268	following	_
26-28	4269-4278	disorders	_
26-29	4279-4280	:	_
26-30	4281-4286	major	_
26-31	4287-4297	depressive	_
26-32	4298-4299	,	_
26-33	4300-4307	bipolar	_
26-34	4308-4309	I	_
26-35	4310-4312	or	_
26-36	4313-4315	II	_
26-37	4316-4317	,	_
26-38	4318-4333	schizoaffective	_
26-39	4334-4335	,	_
26-40	4336-4352	schizophreniform	_
26-41	4353-4354	,	_
26-42	4355-4357	or	_
26-43	4358-4369	generalized	_
26-44	4370-4377	anxiety	_
26-45	4378-4379	.	_

27-1	4380-4388	Analyses	_
27-2	4389-4391	of	_
27-3	4392-4395	the	_
27-4	4396-4403	results	_
27-5	4404-4408	from	_
27-6	4409-4412	the	_
27-7	4413-4414	“	_
27-8	4415-4427	unconfounded	_
27-9	4428-4429	”	_
27-10	4430-4438	subgroup	_
27-11	4439-4441	of	_
27-12	4442-4454	participants	_
27-13	4455-4459	were	_
27-14	4460-4470	consistent	_
27-15	4471-4475	with	_
27-16	4476-4481	those	_
27-17	4482-4484	as	_
27-18	4485-4493	reported	_
27-19	4494-4496	in	_
27-20	4497-4500	the	_
27-21	4501-4505	text	_
27-22	4506-4509	for	_
27-23	4510-4513	the	_
27-24	4514-4519	total	_
27-25	4520-4526	sample	_
27-26	4527-4528	.	_

28-1	4529-4541	Participants	_
28-2	4542-4550	received	_
28-3	4551-4552	a	_
28-4	4553-4563	structured	_
28-5	4564-4573	interview	_
28-6	4574-4583	regarding	_
28-7	4584-4589	their	_
28-8	4590-4598	drinking	_
28-9	4599-4607	patterns	_
28-10	4608-4609	,	_
28-11	4610-4619	including	_
28-12	4620-4626	length	_
28-13	4627-4629	of	_
28-14	4630-4638	sobriety	_
28-15	4639-4640	(	_
28-16	4641-4644	LOS	_
28-17	4645-4646	)	_
28-18	4647-4650	and	_
28-19	4651-4659	duration	_
28-20	4660-4662	of	_
28-21	4663-4668	heavy	_
28-22	4669-4677	drinking	_
28-23	4678-4679	(	_
28-24	4680-4683	DHD	_
28-25	4684-4685	)	_
28-26	4686-4687	,	_
28-27	4688-4692	i.e.	_
28-28	4693-4694	,	_
28-29	4695-4699	more	_
28-30	4700-4704	than	_
28-31	4705-4707	21	_
28-32	4708-4714	drinks	_
28-33	4715-4718	per	_
28-34	4719-4723	week	_
28-35	4724-4725	(	_
28-36	4726-4729	one	_
28-37	4730-4735	drink	_
28-38	4736-4737	:	_
28-39	4738-4741	355	_
28-40	4742-4744	ml	_
28-41	4745-4749	beer	_
28-42	4750-4751	,	_
28-43	4752-4755	148	_
28-44	4756-4758	ml	_
28-45	4759-4763	wine	_
28-46	4764-4765	,	_
28-47	4766-4768	or	_
28-48	4769-4771	44	_
28-49	4772-4774	ml	_
28-50	4775-4779	hard	_
28-51	4780-4786	liquor	_
28-52	4787-4788	)	_
28-53	4789-4790	.	_

29-1	4791-4798	At-risk	_
29-2	4799-4807	drinking	_
29-3	4808-4810	is	_
29-4	4811-4821	considered	_
29-5	4822-4824	to	_
29-6	4825-4827	be	_
29-7	4828-4832	more	_
29-8	4833-4837	than	_
29-9	4838-4843	three	_
29-10	4844-4850	drinks	_
29-11	4851-4854	per	_
29-12	4855-4859	week	_
29-13	4860-4861	.	_

30-1	4862-4874	Additionally	_
30-2	4875-4876	,	_
30-3	4877-4878	a	_
30-4	4879-4887	Quantity	_
30-5	4888-4897	Frequency	_
30-6	4898-4903	Index	_
30-7	4904-4909	which	_
30-8	4910-4917	factors	_
30-9	4918-4921	the	_
30-10	4922-4928	amount	_
30-11	4929-4930	,	_
30-12	4931-4935	type	_
30-13	4936-4937	,	_
30-14	4938-4941	and	_
30-15	4942-4951	frequency	_
30-16	4952-4954	of	_
30-17	4955-4962	alcohol	_
30-18	4963-4968	usage	_
30-19	4969-4970	(	_
30-20	4971-4978	roughly	_
30-21	4979-4992	corresponding	_
30-22	4993-4995	to	_
30-23	4996-5002	number	_
30-24	5003-5005	of	_
30-25	5006-5011	daily	_
30-26	5012-5018	drinks	_
30-27	5019-5020	,	_
30-28	5021-5023	DD	_
30-29	5024-5025	)	_
30-30	5026-5030	over	_
30-31	5031-5034	the	_
30-32	5035-5039	last	_
30-33	5040-5043	six	_
30-34	5044-5050	months	_
30-35	5051-5052	(	_
30-36	5053-5056	for	_
30-37	5057-5060	the	_
30-38	5061-5063	NC	_
30-39	5064-5076	participants	_
30-40	5077-5078	)	_
30-41	5079-5080	,	_
30-42	5081-5083	or	_
30-43	5084-5088	over	_
30-44	5089-5092	the	_
30-45	5093-5096	six	_
30-46	5097-5103	months	_
30-47	5104-5113	preceding	_
30-48	5114-5123	cessation	_
30-49	5124-5126	of	_
30-50	5127-5135	drinking	_
30-51	5136-5137	(	_
30-52	5138-5141	for	_
30-53	5142-5145	the	_
30-54	5146-5149	ALC	_
30-55	5150-5162	participants	_
30-56	5163-5164	)	_
30-57	5165-5166	,	_
30-58	5167-5170	was	_
30-59	5171-5181	calculated	_
30-60	5182-5185	for	_
30-61	5186-5190	each	_
30-62	5191-5202	participant	_
30-63	5203-5204	.	_

31-1	5205-5213	Subjects	_
31-2	5214-5218	also	_
31-3	5219-5223	were	_
31-4	5224-5229	asked	_
31-5	5230-5235	about	_
31-6	5236-5242	family	_
31-7	5243-5250	history	_
31-8	5251-5253	of	_
31-9	5254-5264	alcoholism	_
31-10	5265-5266	(	_
31-11	5267-5270	see	_
31-12	5271-5283	Supplemental	_
31-13	5284-5289	Table	_
31-14	5290-5291	1	_
31-15	5292-5293	)	_
31-16	5294-5295	.	_

32-1	5296-5299	The	_
32-2	5300-5303	ALC	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
32-3	5304-5316	participants	_
32-4	5317-5320	met	_
32-5	5321-5327	DSM-IV	_
32-6	5328-5336	criteria	_
32-7	5337-5340	for	_
32-8	5341-5348	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
32-9	5349-5354	abuse	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
32-10	5355-5357	or	_
32-11	5358-5368	dependence	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence
32-12	5369-5372	and	_
32-13	5373-5378	drank	_
32-14	5379-5386	heavily	_
32-15	5387-5390	for	_
32-16	5391-5392	a	_
32-17	5393-5399	period	_
32-18	5400-5402	of	_
32-19	5403-5405	at	_
32-20	5406-5411	least	_
32-21	5412-5416	five	_
32-22	5417-5422	years	_
32-23	5423-5425	in	_
32-24	5426-5431	their	_
32-25	5432-5437	lives	_
32-26	5438-5439	;	_
32-27	5440-5444	they	_
32-28	5445-5448	had	_
32-29	5449-5458	abstained	_
32-30	5459-5463	from	_
32-31	5464-5471	alcohol	_
32-32	5472-5475	for	_
32-33	5476-5478	at	_
32-34	5479-5484	least	_
32-35	5485-5489	four	_
32-36	5490-5495	weeks	_
32-37	5496-5501	prior	_
32-38	5502-5504	to	_
32-39	5505-5512	testing	_
32-40	5513-5514	(	_
32-41	5515-5520	range	_
32-42	5521-5523	of	_
32-43	5524-5534	abstinence	_
32-44	5535-5536	:	_
32-45	5537-5541	four	_
32-46	5542-5547	weeks	_
32-47	5548-5550	to	_
32-48	5551-5553	38	_
32-49	5554-5559	years	_
32-50	5560-5561	)	_
32-51	5562-5563	,	_
32-52	5564-5570	except	_
32-53	5571-5574	for	_
32-54	5575-5578	one	_
32-55	5579-5582	ALC	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
32-56	5583-5588	woman	_
32-57	5589-5592	and	_
32-58	5593-5596	two	_
32-59	5597-5600	ALC	http://maven.renci.org/NeuroBridge/neurobridge#Menopause
32-60	5601-5604	men	http://maven.renci.org/NeuroBridge/neurobridge#Menopause
32-61	5605-5609	with	_
32-62	5610-5617	shorter	_
32-63	5618-5626	sobriety	_
32-64	5627-5634	periods	_
32-65	5635-5638	and	_
32-66	5639-5642	who	_
32-67	5643-5647	were	_
32-68	5648-5656	excluded	_
32-69	5657-5661	from	_
32-70	5662-5665	the	_
32-71	5666-5678	unconfounded	_
32-72	5679-5687	subgroup	_
32-73	5688-5689	.	_

33-1	5690-5696	Length	_
33-2	5697-5699	of	_
33-3	5700-5708	sobriety	_
33-4	5709-5712	was	_
33-5	5713-5724	ascertained	_
33-6	5725-5729	with	_
33-7	5730-5737	several	_
33-8	5738-5751	comprehensive	_
33-9	5752-5762	interviews	_
33-10	5763-5767	over	_
33-11	5768-5776	multiple	_
33-12	5777-5784	testing	_
33-13	5785-5793	sessions	_
33-14	5794-5795	,	_
33-15	5796-5798	in	_
33-16	5799-5804	which	_
33-17	5805-5808	the	_
33-18	5809-5813	date	_
33-19	5814-5816	of	_
33-20	5817-5821	last	_
33-21	5822-5827	drink	_
33-22	5828-5831	was	_
33-23	5832-5840	obtained	_
33-24	5841-5844	and	_
33-25	5845-5853	examined	_
33-26	5854-5857	for	_
33-27	5858-5869	consistency	_
33-28	5870-5876	across	_
33-29	5877-5885	sessions	_
33-30	5886-5887	.	_

34-1	5888-5897	Alcoholic	_
34-2	5898-5901	men	_
34-3	5902-5905	and	_
34-4	5906-5911	women	_
34-5	5912-5915	did	_
34-6	5916-5919	not	_
34-7	5920-5926	differ	_
34-8	5927-5929	by	_
34-9	5930-5932	DD	_
34-10	5933-5934	,	_
34-11	5935-5938	DHD	_
34-12	5939-5940	,	_
34-13	5941-5943	or	_
34-14	5944-5947	LOS	_
34-15	5948-5949	.	_

35-1	5950-5955	Tests	_
35-2	5956-5958	of	_
35-3	5959-5971	intelligence	_
35-4	5972-5973	,	_
35-5	5974-5980	memory	_
35-6	5981-5982	,	_
35-7	5983-5986	and	_
35-8	5987-5993	affect	_
35-9	5994-5998	were	_
35-10	5999-6011	administered	_
35-11	6012-6013	,	_
35-12	6014-6023	including	_
35-13	6024-6027	the	_
35-14	6028-6036	Wechsler	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
35-15	6037-6042	Adult	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
35-16	6043-6055	Intelligence	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
35-17	6056-6061	Scale	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
35-18	6062-6063	,	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
35-19	6064-6069	Third	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
35-20	6070-6077	Edition	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
35-21	6078-6079	(	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
35-22	6080-6088	WAIS-III	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
35-23	6089-6090	)	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
35-24	6091-6094	for	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
35-25	6095-6105	Full-Scale	http://maven.renci.org/NeuroBridge/neurobridge#Scale
35-26	6106-6108	IQ	http://maven.renci.org/NeuroBridge/neurobridge#Scale
35-27	6109-6110	(	http://maven.renci.org/NeuroBridge/neurobridge#Scale
35-28	6111-6115	FSIQ	http://maven.renci.org/NeuroBridge/neurobridge#Scale
35-29	6116-6117	)	http://maven.renci.org/NeuroBridge/neurobridge#Scale
35-30	6118-6119	,	_
35-31	6120-6126	Verbal	http://maven.renci.org/NeuroBridge/neurobridge#VerbalFluencyTask
35-32	6127-6129	IQ	http://maven.renci.org/NeuroBridge/neurobridge#VerbalFluencyTask
35-33	6130-6131	(	http://maven.renci.org/NeuroBridge/neurobridge#VerbalFluencyTask
35-34	6132-6135	VIQ	http://maven.renci.org/NeuroBridge/neurobridge#VerbalFluencyTask
35-35	6136-6137	)	http://maven.renci.org/NeuroBridge/neurobridge#VerbalFluencyTask
35-36	6138-6139	,	_
35-37	6140-6151	Performance	http://maven.renci.org/NeuroBridge/neurobridge#PersonalandSocialPerformanceScale
35-38	6152-6154	IQ	http://maven.renci.org/NeuroBridge/neurobridge#PersonalandSocialPerformanceScale
35-39	6155-6156	(	http://maven.renci.org/NeuroBridge/neurobridge#PersonalandSocialPerformanceScale
35-40	6157-6160	PIQ	http://maven.renci.org/NeuroBridge/neurobridge#PersonalandSocialPerformanceScale
35-41	6161-6162	)	http://maven.renci.org/NeuroBridge/neurobridge#PersonalandSocialPerformanceScale
35-42	6163-6164	,	_
35-43	6165-6168	and	http://maven.renci.org/NeuroBridge/neurobridge#PhysicalMeasurement
35-44	6169-6176	Working	http://maven.renci.org/NeuroBridge/neurobridge#WorkingMemoryTask
35-45	6177-6183	Memory	http://maven.renci.org/NeuroBridge/neurobridge#WorkingMemoryTask
35-46	6184-6189	Index	http://maven.renci.org/NeuroBridge/neurobridge#WorkingMemoryTask
35-47	6190-6191	(	http://maven.renci.org/NeuroBridge/neurobridge#WorkingMemoryTask
35-48	6192-6195	WMI	http://maven.renci.org/NeuroBridge/neurobridge#WorkingMemoryTask
35-49	6196-6197	)	http://maven.renci.org/NeuroBridge/neurobridge#WorkingMemoryTask
35-50	6198-6199	;	_
35-51	6200-6203	the	_
35-52	6204-6212	Wechsler	http://maven.renci.org/NeuroBridge/neurobridge#Revised
35-53	6213-6219	Memory	http://maven.renci.org/NeuroBridge/neurobridge#Revised
35-54	6220-6225	Scale	http://maven.renci.org/NeuroBridge/neurobridge#Revised
35-55	6226-6227	,	http://maven.renci.org/NeuroBridge/neurobridge#Revised
35-56	6228-6233	Third	http://maven.renci.org/NeuroBridge/neurobridge#Revised
35-57	6234-6241	Edition	http://maven.renci.org/NeuroBridge/neurobridge#Revised
35-58	6242-6243	(	http://maven.renci.org/NeuroBridge/neurobridge#Revised
35-59	6244-6251	WMS-III	http://maven.renci.org/NeuroBridge/neurobridge#Revised
35-60	6252-6253	)	http://maven.renci.org/NeuroBridge/neurobridge#Revised
35-61	6254-6257	for	http://maven.renci.org/NeuroBridge/neurobridge#Revised
35-62	6258-6265	Delayed	http://maven.renci.org/NeuroBridge/neurobridge#Revised
35-63	6266-6272	Memory	http://maven.renci.org/NeuroBridge/neurobridge#Revised
35-64	6273-6274	;	_
35-65	6275-6278	the	_
35-66	6279-6283	HRSD	http://maven.renci.org/NeuroBridge/neurobridge#CenterForEpidemiologicStudiesDepressionScale
35-67	6284-6287	for	http://maven.renci.org/NeuroBridge/neurobridge#CenterForEpidemiologicStudiesDepressionScale
35-68	6288-6298	depression	http://maven.renci.org/NeuroBridge/neurobridge#CenterForEpidemiologicStudiesDepressionScale
35-69	6299-6300	;	_
35-70	6301-6304	and	_
35-71	6305-6308	the	_
35-72	6309-6317	Multiple	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
35-73	6318-6324	Affect	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
35-74	6325-6334	Adjective	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
35-75	6335-6340	Check	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
35-76	6341-6345	List	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
35-77	6346-6347	(	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
35-78	6348-6353	MAACL	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
35-79	6354-6355	)	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
35-80	6356-6359	for	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
35-81	6360-6367	anxiety	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
35-82	6368-6369	.	_

36-1	6370-6373	2.3	_
36-2	6374-6375	.	_

37-1	6376-6379	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
37-2	6380-6391	acquisition	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
37-3	6392-6395	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
37-4	6396-6401	scans	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
37-5	6402-6406	were	_
37-6	6407-6415	obtained	_
37-7	6416-6418	on	_
37-8	6419-6420	a	_
37-9	6421-6428	Siemens	http://maven.renci.org/NeuroBridge/neurobridge#DateTimeUnit
37-10	6429-6436	3-Tesla	http://maven.renci.org/NeuroBridge/neurobridge#DateTimeUnit
37-11	6437-6440	TIM	http://maven.renci.org/NeuroBridge/neurobridge#DateTimeUnit
37-12	6441-6445	Trio	http://maven.renci.org/NeuroBridge/neurobridge#DateTimeUnit
37-13	6446-6453	scanner	http://maven.renci.org/NeuroBridge/neurobridge#DateTimeUnit
37-14	6454-6458	with	_
37-15	6459-6461	an	_
37-16	6462-6471	8-channel	_
37-17	6472-6476	head	_
37-18	6477-6481	coil	_
37-19	6482-6483	(	_
37-20	6484-6491	Siemens	_
37-21	6492-6499	Medical	_
37-22	6500-6509	Solutions	_
37-23	6510-6513	USA	_
37-24	6514-6515	,	_
37-25	6516-6520	Inc.	_
37-26	6521-6522	,	_
37-27	6523-6530	Malvern	_
37-28	6531-6532	,	_
37-29	6533-6545	Pennsylvania	_
37-30	6546-6547	)	_
37-31	6548-6549	.	_

38-1	6550-6555	Image	_
38-2	6556-6568	acquisitions	_
38-3	6569-6577	included	_
38-4	6578-6586	sagittal	_
38-5	6587-6592	scout	_
38-6	6593-6596	and	_
38-7	6597-6600	two	_
38-8	6601-6612	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
38-9	6613-6620	MP-RAGE	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
38-10	6621-6627	series	_
38-11	6628-6631	for	_
38-12	6632-6642	volumetric	_
38-13	6643-6651	analysis	_
38-14	6652-6653	:	_
38-15	6654-6663	TR=2530ms	_
38-16	6664-6665	,	_
38-17	6666-6675	TE=3.39ms	_
38-18	6676-6677	,	_
38-19	6678-6687	TI=1100ms	_
38-20	6688-6689	,	_
38-21	6690-6703	flip-angle=7°	_
38-22	6704-6705	,	_
38-23	6706-6723	Field-of-View=256	_
38-24	6724-6725	,	_
38-25	6726-6748	slice-thickness=1.33mm	_
38-26	6749-6750	,	_
38-27	6751-6771	number-of-slices=128	_
38-28	6772-6782	contiguous	_
38-29	6783-6784	,	_
38-30	6785-6793	sagittal	_
38-31	6794-6800	images	_
38-32	6801-6803	of	_
38-33	6804-6807	the	_
38-34	6808-6814	entire	_
38-35	6815-6820	brain	_
38-36	6821-6822	,	_
38-37	6823-6837	matrix=256×256	_
38-38	6838-6839	,	_
38-39	6840-6863	number-of-excitations=2	_
38-40	6864-6865	.	_

39-1	6866-6869	The	_
39-2	6870-6873	two	_
39-3	6874-6881	MP-RAGE	_
39-4	6882-6888	series	_
39-5	6889-6893	were	_
39-6	6894-6902	averaged	_
39-7	6903-6904	,	_
39-8	6905-6909	then	_
39-9	6910-6913	the	_
39-10	6914-6922	averaged	_
39-11	6923-6929	series	_
39-12	6930-6933	was	_
39-13	6934-6943	re-sliced	_
39-14	6944-6946	in	_
39-15	6947-6948	a	_
39-16	6949-6957	standard	_
39-17	6958-6965	coronal	_
39-18	6966-6983	three-dimensional	_
39-19	6984-6989	brain	_
39-20	6990-7000	coordinate	_
39-21	7001-7007	system	_
39-22	7008-7009	.	_

40-1	7010-7016	Images	_
40-2	7017-7021	were	_
40-3	7022-7034	re-formatted	_
40-4	7035-7037	to	_
40-5	7038-7046	standard	_
40-6	7047-7054	spatial	_
40-7	7055-7066	orientation	_
40-8	7067-7068	,	_
40-9	7069-7072	but	_
40-10	7073-7076	not	_
40-11	7077-7085	rescaled	_
40-12	7086-7088	in	_
40-13	7089-7093	size	_
40-14	7094-7095	.	_

41-1	7096-7099	2.4	_
41-2	7100-7101	.	_

42-1	7102-7105	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
42-2	7106-7118	morphometric	_
42-3	7119-7127	analyses	_
42-4	7128-7133	Image	_
42-5	7134-7142	analyses	_
42-6	7143-7151	followed	_
42-7	7152-7166	semi-automated	_
42-8	7167-7177	procedures	_
42-9	7178-7179	.	_

43-1	7180-7186	Images	_
43-2	7187-7191	were	_
43-3	7192-7201	inspected	_
43-4	7202-7205	for	_
43-5	7206-7211	gross	_
43-6	7212-7225	abnormalities	_
43-7	7226-7227	,	_
43-8	7228-7231	and	_
43-9	7232-7240	cortical	_
43-10	7241-7245	gray	_
43-11	7246-7252	matter	_
43-12	7253-7254	,	_
43-13	7255-7260	white	_
43-14	7261-7267	matter	_
43-15	7268-7269	,	_
43-16	7270-7281	subcortical	_
43-17	7282-7292	structures	_
43-18	7293-7294	,	_
43-19	7295-7298	and	_
43-20	7299-7309	ventricles	_
43-21	7310-7314	were	_
43-22	7315-7323	manually	_
43-23	7324-7333	segmented	_
43-24	7334-7336	on	_
43-25	7337-7348	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
43-26	7349-7355	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
43-27	7356-7361	using	_
43-28	7362-7363	a	_
43-29	7364-7381	computer-assisted	_
43-30	7382-7390	approach	_
43-31	7391-7392	.	_

44-1	7393-7402	Neocortex	_
44-2	7403-7406	was	_
44-3	7407-7417	subdivided	_
44-4	7418-7425	further	_
44-5	7426-7430	into	_
44-6	7431-7443	parcellation	_
44-7	7444-7449	units	_
44-8	7450-7451	,	_
44-9	7452-7461	involving	_
44-10	7462-7463	a	_
44-11	7464-7470	number	_
44-12	7471-7473	of	_
44-13	7474-7480	manual	_
44-14	7481-7484	and	_
44-15	7485-7502	computer-assisted	_
44-16	7503-7513	operations	_
44-17	7514-7515	.	_

45-1	7516-7524	Cortical	_
45-2	7525-7535	subregions	_
45-3	7536-7538	of	_
45-4	7539-7542	the	_
45-5	7543-7549	reward	_
45-6	7550-7557	network	_
45-7	7558-7562	were	_
45-8	7563-7570	derived	_
45-9	7571-7572	:	_
45-10	7573-7578	DLPFC	_
45-11	7579-7580	(	_
45-12	7581-7588	defined	_
45-13	7589-7591	as	_
45-14	7592-7595	the	_
45-15	7596-7599	sum	_
45-16	7600-7602	of	_
45-17	7603-7606	the	_
45-18	7607-7619	dorsolateral	_
45-19	7620-7636	superior-frontal	_
45-20	7637-7640	and	_
45-21	7641-7655	middle-frontal	_
45-22	7656-7660	gyri	_
45-23	7661-7662	,	_
45-24	7663-7676	approximating	_
45-25	7677-7685	Brodmann	_
45-26	7686-7691	areas	_
45-27	7692-7693	8	_
45-28	7694-7695	,	_
45-29	7696-7697	9	_
45-30	7698-7699	,	_
45-31	7700-7703	and	_
45-32	7704-7706	46	_
45-33	7707-7708	)	_
45-34	7709-7710	,	_
45-35	7711-7718	insular	_
45-36	7719-7720	,	_
45-37	7721-7732	subcallosal	_
45-38	7733-7734	,	_
45-39	7735-7748	orbitofrontal	_
45-40	7749-7750	,	_
45-41	7751-7754	and	_
45-42	7755-7764	cingulate	_
45-43	7765-7773	cortices	_
45-44	7774-7775	,	_
45-45	7776-7791	parahippocampal	_
45-46	7792-7797	gyrus	_
45-47	7798-7799	,	_
45-48	7800-7803	and	_
45-49	7804-7812	temporal	_
45-50	7813-7817	pole	_
45-51	7818-7819	.	_

46-1	7820-7824	Gray	_
46-2	7825-7831	matter	_
46-3	7832-7843	subcortical	_
46-4	7844-7854	structures	_
46-5	7855-7857	in	_
46-6	7858-7861	the	_
46-7	7862-7868	reward	_
46-8	7869-7876	network	_
46-9	7877-7885	included	_
46-10	7886-7889	NAc	_
46-11	7890-7891	,	_
46-12	7892-7900	amygdala	_
46-13	7901-7902	,	_
46-14	7903-7914	hippocampus	_
46-15	7915-7916	,	_
46-16	7917-7920	and	_
46-17	7921-7924	VDC	_
46-18	7925-7926	.	_

47-1	7927-7930	For	_
47-2	7931-7941	volumetric	_
47-3	7942-7953	comparisons	_
47-4	7954-7956	to	_
47-5	7957-7963	reward	_
47-6	7964-7971	network	_
47-7	7972-7979	regions	_
47-8	7980-7981	,	_
47-9	7982-7984	we	_
47-10	7985-7993	included	_
47-11	7994-8002	analyses	_
47-12	8003-8005	of	_
47-13	8006-8013	sensory	_
47-14	8014-8020	cortex	_
47-15	8021-8022	(	_
47-16	8023-8029	cuneus	_
47-17	8030-8031	)	_
47-18	8032-8035	and	_
47-19	8036-8047	subcortical	_
47-20	8048-8049	(	_
47-21	8050-8056	dorsal	_
47-22	8057-8065	striatum	_
47-23	8066-8067	)	_
47-24	8068-8075	regions	_
47-25	8076-8077	.	_

48-1	8078-8090	Segmentation	_
48-2	8091-8094	and	_
48-3	8095-8103	cortical	_
48-4	8104-8116	parcellation	_
48-5	8117-8121	were	_
48-6	8122-8132	supervised	_
48-7	8133-8135	by	_
48-8	8136-8139	our	_
48-9	8140-8154	neuroanatomist	_
48-10	8155-8156	(	_
48-11	8157-8159	NM	_
48-12	8160-8161	)	_
48-13	8162-8163	.	_

49-1	8164-8173	Blindness	_
49-2	8174-8176	to	_
49-3	8177-8182	group	_
49-4	8183-8193	assignment	_
49-5	8194-8197	was	_
49-6	8198-8208	maintained	_
49-7	8209-8215	during	_
49-8	8216-8224	analyses	_
49-9	8225-8226	.	_

50-1	8227-8231	High	_
50-2	8232-8243	inter-rater	_
50-3	8244-8247	and	_
50-4	8248-8259	intra-rater	_
50-5	8260-8271	reliability	_
50-6	8272-8274	of	_
50-7	8275-8280	these	_
50-8	8281-8288	methods	_
50-9	8289-8293	have	_
50-10	8294-8298	been	_
50-11	8299-8310	established	_
50-12	8311-8312	(	_
50-13	8313-8314	;	_
50-14	8315-8316	;	_
50-15	8317-8318	)	_
50-16	8319-8320	.	_

51-1	8321-8330	Estimated	_
51-2	8331-8336	total	_
51-3	8337-8349	intracranial	_
51-4	8350-8356	volume	_
51-5	8357-8360	was	_
51-6	8361-8369	obtained	_
51-7	8370-8375	using	_
51-8	8376-8386	FreeSurfer	_
51-9	8387-8390	5.3	_
51-10	8391-8392	,	_
51-11	8393-8395	an	_
51-12	8396-8405	automated	_
51-13	8406-8415	procedure	_
51-14	8416-8417	.	_

52-1	8418-8419	A	_
52-2	8420-8427	primary	_
52-3	8428-8435	purpose	_
52-4	8436-8438	of	_
52-5	8439-8442	our	_
52-6	8443-8448	study	_
52-7	8449-8452	was	_
52-8	8453-8455	to	_
52-9	8456-8465	determine	_
52-10	8466-8469	sex	_
52-11	8470-8481	differences	_
52-12	8482-8484	in	_
52-13	8485-8488	the	_
52-14	8489-8494	brain	_
52-15	8495-8497	's	_
52-16	8498-8504	reward	_
52-17	8505-8511	system	_
52-18	8512-8514	in	_
52-19	8515-8526	individuals	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
52-20	8527-8531	with	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
52-21	8532-8539	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
52-22	8540-8543	Use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
52-23	8544-8552	Disorder	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
52-24	8553-8554	.	_

53-1	8555-8557	We	_
53-2	8558-8563	chose	_
53-3	8564-8566	to	_
53-4	8567-8570	use	_
53-5	8571-8572	a	_
53-6	8573-8587	semi-automated	_
53-7	8588-8605	observer-assisted	_
53-8	8606-8612	method	_
53-9	8613-8615	to	_
53-10	8616-8623	measure	_
53-11	8624-8627	the	_
53-12	8628-8634	reward	_
53-13	8635-8641	volume	_
53-14	8642-8645	and	_
53-15	8646-8649	its	_
53-16	8650-8660	components	_
53-17	8661-8662	,	_
53-18	8663-8669	rather	_
53-19	8670-8674	than	_
53-20	8675-8679	more	_
53-21	8680-8689	automated	_
53-22	8690-8700	techniques	_
53-23	8701-8702	,	_
53-24	8703-8706	for	_
53-25	8707-8710	two	_
53-26	8711-8718	primary	_
53-27	8719-8726	reasons	_
53-28	8727-8728	.	_

54-1	8729-8736	Firstly	_
54-2	8737-8738	,	_
54-3	8739-8741	we	_
54-4	8742-8746	have	_
54-5	8747-8757	previously	_
54-6	8758-8767	published	_
54-7	8768-8769	a	_
54-8	8770-8780	comparison	_
54-9	8781-8788	between	_
54-10	8789-8792	the	_
54-11	8793-8799	method	_
54-12	8800-8804	used	_
54-13	8805-8807	in	_
54-14	8808-8811	the	_
54-15	8812-8819	current	_
54-16	8820-8827	project	_
54-17	8828-8831	and	_
54-18	8832-8835	the	_
54-19	8836-8845	automated	_
54-20	8846-8856	Freesurfer	_
54-21	8857-8863	method	_
54-22	8864-8865	,	_
54-23	8866-8868	in	_
54-24	8869-8874	which	_
54-25	8875-8877	we	_
54-26	8878-8888	identified	_
54-27	8889-8892	the	_
54-28	8893-8903	trade-offs	_
54-29	8904-8907	for	_
54-30	8908-8912	each	_
54-31	8913-8921	approach	_
54-32	8922-8923	.	_

55-1	8924-8936	Specifically	_
55-2	8937-8938	,	_
55-3	8939-8942	the	_
55-4	8943-8953	advantages	_
55-5	8954-8956	of	_
55-6	8957-8962	using	_
55-7	8963-8968	fully	_
55-8	8969-8978	automated	_
55-9	8979-8986	methods	_
55-10	8987-8991	such	_
55-11	8992-8994	as	_
55-12	8995-9005	FreeSurfer	_
55-13	9006-9009	are	_
55-14	9010-9015	speed	_
55-15	9016-9019	and	_
55-16	9020-9023	low	_
55-17	9024-9028	cost	_
55-18	9029-9030	,	_
55-19	9031-9034	and	_
55-20	9035-9039	thus	_
55-21	9040-9043	may	_
55-22	9044-9046	be	_
55-23	9047-9057	preferable	_
55-24	9058-9061	for	_
55-25	9062-9066	some	_
55-26	9067-9074	studies	_
55-27	9075-9076	.	_

56-1	9077-9079	In	_
56-2	9080-9084	fact	_
56-3	9085-9086	,	_
56-4	9087-9089	we	_
56-5	9090-9093	did	_
56-6	9094-9097	use	_
56-7	9098-9108	FreeSurfer	_
56-8	9109-9111	in	_
56-9	9112-9115	the	_
56-10	9116-9123	present	_
56-11	9124-9129	study	_
56-12	9130-9133	for	_
56-13	9134-9143	measuring	_
56-14	9144-9153	estimated	_
56-15	9154-9159	total	_
56-16	9160-9172	intracranial	_
56-17	9173-9179	volume	_
56-18	9180-9181	.	_

57-1	9182-9189	However	_
57-2	9190-9191	,	_
57-3	9192-9201	automated	_
57-4	9202-9210	measures	_
57-5	9211-9214	are	_
57-6	9215-9219	more	_
57-7	9220-9225	prone	_
57-8	9226-9228	to	_
57-9	9229-9243	coregistration	_
57-10	9244-9252	problems	_
57-11	9253-9254	,	_
57-12	9255-9263	atlasing	_
57-13	9264-9276	misalignment	_
57-14	9277-9278	,	_
57-15	9279-9282	and	_
57-16	9283-9288	other	_
57-17	9289-9298	artifacts	_
57-18	9299-9300	,	_
57-19	9301-9304	and	_
57-20	9305-9308	are	_
57-21	9309-9312	not	_
57-22	9313-9315	as	_
57-23	9316-9324	accurate	_
57-24	9325-9326	,	_
57-25	9327-9339	particularly	_
57-26	9340-9343	for	_
57-27	9344-9353	measuring	_
57-28	9354-9357	the	_
57-29	9358-9363	small	_
57-30	9364-9371	regions	_
57-31	9372-9374	in	_
57-32	9375-9378	the	_
57-33	9379-9385	reward	_
57-34	9386-9392	system	_
57-35	9393-9394	.	_

58-1	9395-9397	By	_
58-2	9398-9408	comparison	_
58-3	9409-9410	,	_
58-4	9411-9414	the	_
58-5	9415-9421	method	_
58-6	9422-9426	used	_
58-7	9427-9429	in	_
58-8	9430-9433	the	_
58-9	9434-9441	present	_
58-10	9442-9447	study	_
58-11	9448-9450	is	_
58-12	9451-9454	the	_
58-13	9455-9459	gold	_
58-14	9460-9468	standard	_
58-15	9469-9472	for	_
58-16	9473-9486	neuroanatomic	_
58-17	9487-9495	accuracy	_
58-18	9496-9497	,	_
58-19	9498-9501	and	_
58-20	9502-9509	ensures	_
58-21	9510-9519	precision	_
58-22	9520-9523	and	_
58-23	9524-9535	reliability	_
58-24	9536-9538	in	_
58-25	9539-9548	measuring	_
58-26	9549-9557	regional	_
58-27	9558-9563	brain	_
58-28	9564-9572	networks	_
58-29	9573-9574	.	_

59-1	9575-9583	Secondly	_
59-2	9584-9585	,	_
59-3	9586-9591	since	_
59-4	9592-9594	we	_
59-5	9595-9598	had	_
59-6	9599-9609	previously	_
59-7	9610-9618	observed	_
59-8	9619-9622	and	_
59-9	9623-9631	reported	_
59-10	9632-9645	abnormalities	_
59-11	9646-9648	in	_
59-12	9649-9652	the	_
59-13	9653-9659	reward	_
59-14	9660-9666	system	_
59-15	9667-9669	of	_
59-16	9670-9673	men	_
59-17	9674-9678	with	_
59-18	9679-9686	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
59-19	9687-9690	Use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
59-20	9691-9699	Disorder	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
59-21	9700-9701	,	_
59-22	9702-9704	we	_
59-23	9705-9711	wanted	_
59-24	9712-9714	to	_
59-25	9715-9718	use	_
59-26	9719-9722	the	_
59-27	9723-9727	same	_
59-28	9728-9742	semi-automated	_
59-29	9743-9746	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
59-30	9747-9754	methods	_
59-31	9755-9757	as	_
59-32	9758-9760	in	_
59-33	9761-9765	that	_
59-34	9766-9771	prior	_
59-35	9772-9778	report	_
59-36	9779-9780	,	_
59-37	9781-9783	to	_
59-38	9784-9790	ensure	_
59-39	9791-9802	consistency	_
59-40	9803-9809	across	_
59-41	9810-9817	studies	_
59-42	9818-9819	.	_

60-1	9820-9823	2.5	_
60-2	9824-9825	.	_

61-1	9826-9837	Statistical	_
61-2	9838-9846	analyses	_
61-3	9847-9858	Statistical	_
61-4	9859-9867	analyses	_
61-5	9868-9872	were	_
61-6	9873-9882	performed	_
61-7	9883-9888	using	_
61-8	9889-9892	JMP	_
61-9	9893-9896	Pro	_
61-10	9897-9905	software	_
61-11	9906-9907	(	_
61-12	9908-9915	version	_
61-13	9916-9918	11	_
61-14	9919-9920	,	_
61-15	9921-9924	SAS	_
61-16	9925-9934	Institute	_
61-17	9935-9936	,	_
61-18	9937-9941	Inc.	_
61-19	9942-9943	,	_
61-20	9944-9948	Cary	_
61-21	9949-9950	,	_
61-22	9951-9953	NC	_
61-23	9954-9955	)	_
61-24	9956-9957	.	_

62-1	9958-9960	We	_
62-2	9961-9968	applied	_
62-3	9969-9970	a	_
62-4	9971-9982	multi-level	_
62-5	9983-9987	data	_
62-6	9988-9996	analysis	_
62-7	9997-10005	approach	_
62-8	10006-10007	.	_

63-1	10008-10013	First	_
63-2	10014-10015	,	_
63-3	10016-10022	global	_
63-4	10023-10033	volumetric	_
63-5	10034-10039	brain	_
63-6	10040-10048	measures	_
63-7	10049-10050	(	_
63-8	10051-10054	cm3	_
63-9	10055-10056	)	_
63-10	10057-10061	were	_
63-11	10062-10070	assessed	_
63-12	10071-10073	to	_
63-13	10074-10083	determine	_
63-14	10084-10086	if	_
63-15	10087-10092	there	_
63-16	10093-10097	were	_
63-17	10098-10116	alcoholism-related	_
63-18	10117-10119	or	_
63-19	10120-10134	gender-related	_
63-20	10135-10146	differences	_
63-21	10147-10149	in	_
63-22	10150-10155	brain	_
63-23	10156-10157	,	_
63-24	10158-10166	cerebrum	_
63-25	10167-10168	,	_
63-26	10169-10177	cortical	_
63-27	10178-10182	gray	_
63-28	10183-10189	matter	_
63-29	10190-10191	,	_
63-30	10192-10200	cerebral	_
63-31	10201-10206	white	_
63-32	10207-10213	matter	_
63-33	10214-10215	,	_
63-34	10216-10218	or	_
63-35	10219-10230	ventricular	_
63-36	10231-10238	volumes	_
63-37	10239-10240	.	_

64-1	10241-10247	Second	_
64-2	10248-10249	,	_
64-3	10250-10252	we	_
64-4	10253-10261	assessed	_
64-5	10262-10265	the	_
64-6	10266-10272	reward	_
64-7	10273-10280	network	_
64-8	10281-10283	as	_
64-9	10284-10285	a	_
64-10	10286-10291	whole	_
64-11	10292-10293	(	_
64-12	10294-10297	sum	_
64-13	10298-10300	of	_
64-14	10301-10304	all	_
64-15	10305-10311	reward	_
64-16	10312-10319	network	_
64-17	10320-10327	regions	_
64-18	10328-10329	)	_
64-19	10330-10332	to	_
64-20	10333-10342	determine	_
64-21	10343-10350	whether	_
64-22	10351-10354	the	_
64-23	10355-10361	entire	_
64-24	10362-10368	reward	_
64-25	10369-10376	network	_
64-26	10377-10389	specifically	_
64-27	10390-10393	was	_
64-28	10394-10402	affected	_
64-29	10403-10405	in	_
64-30	10406-10416	alcoholism	_
64-31	10417-10418	.	_

65-1	10419-10424	Third	_
65-2	10425-10426	,	_
65-3	10427-10429	we	_
65-4	10430-10438	analyzed	_
65-5	10439-10442	the	_
65-6	10443-10453	individual	_
65-7	10454-10463	component	_
65-8	10464-10471	regions	_
65-9	10472-10482	previously	_
65-10	10483-10493	identified	_
65-11	10494-10496	to	_
65-12	10497-10499	be	_
65-13	10500-10509	important	_
65-14	10510-10512	in	_
65-15	10513-10522	addiction	_
65-16	10523-10526	and	_
65-17	10527-10533	reward	_
65-18	10534-10535	(	_
65-19	10536-10539	see	_
65-20	10540-10546	Figure	_
65-21	10547-10548	1	_
65-22	10549-10550	)	_
65-23	10551-10552	.	_

66-1	10553-10560	Because	_
66-2	10561-10565	each	_
66-3	10566-10572	region	_
66-4	10573-10576	has	_
66-5	10577-10581	been	_
66-6	10582-10595	independently	_
66-7	10596-10607	established	_
66-8	10608-10610	in	_
66-9	10611-10614	the	_
66-10	10615-10625	literature	_
66-11	10626-10628	as	_
66-12	10629-10631	an	_
66-13	10632-10636	area	_
66-14	10637-10639	of	_
66-15	10640-10648	interest	_
66-16	10649-10650	,	_
66-17	10651-10654	and	_
66-18	10655-10662	because	_
66-19	10663-10665	we	_
66-20	10666-10673	limited	_
66-21	10674-10677	the	_
66-22	10678-10686	analyses	_
66-23	10687-10689	to	_
66-24	10690-10691	a	_
66-25	10692-10697	small	_
66-26	10698-10701	set	_
66-27	10702-10704	of	_
66-28	10705-10722	hypothesis-driven	_
66-29	10723-10730	regions	_
66-30	10731-10732	,	_
66-31	10733-10737	each	_
66-32	10738-10746	analysis	_
66-33	10747-10750	was	_
66-34	10751-10761	considered	_
66-35	10762-10763	a	_
66-36	10764-10772	separate	_
66-37	10773-10781	research	_
66-38	10782-10790	question	_
66-39	10791-10792	,	_
66-40	10793-10803	mitigating	_
66-41	10804-10807	the	_
66-42	10808-10812	need	_
66-43	10813-10816	for	_
66-44	10817-10825	multiple	_
66-45	10826-10836	comparison	_
66-46	10837-10847	correction	_
66-47	10848-10849	(	_
66-48	10850-10851	;	_
66-49	10852-10855	but	_
66-50	10856-10859	see	_
66-51	10860-10861	)	_
66-52	10862-10863	.	_

67-1	10864-10866	To	_
67-2	10867-10873	reduce	_
67-3	10874-10877	the	_
67-4	10878-10884	number	_
67-5	10885-10887	of	_
67-6	10888-10899	comparisons	_
67-7	10900-10901	,	_
67-8	10902-10905	and	_
67-9	10906-10910	thus	_
67-10	10911-10915	Type	_
67-11	10916-10917	I	_
67-12	10918-10924	errors	_
67-13	10925-10926	,	_
67-14	10927-10930	the	_
67-15	10931-10935	left	_
67-16	10936-10939	and	_
67-17	10940-10945	right	_
67-18	10946-10957	hemispheric	_
67-19	10958-10965	volumes	_
67-20	10966-10970	were	_
67-21	10971-10977	summed	_
67-22	10978-10979	.	_

68-1	10980-10982	In	_
68-2	10983-10988	order	_
68-3	10989-10991	to	_
68-4	10992-11000	identify	_
68-5	11001-11006	brain	_
68-6	11007-11014	regions	_
68-7	11015-11033	disproportionately	_
68-8	11034-11042	affected	_
68-9	11043-11045	by	_
68-10	11046-11056	alcoholism	_
68-11	11057-11066	exceeding	_
68-12	11067-11078	generalized	_
68-13	11079-11086	effects	_
68-14	11087-11089	on	_
68-15	11090-11093	the	_
68-16	11094-11102	cerebrum	_
68-17	11103-11104	,	_
68-18	11105-11107	we	_
68-19	11108-11118	normalized	_
68-20	11119-11122	the	_
68-21	11123-11128	total	_
68-22	11129-11135	reward	_
68-23	11136-11142	region	_
68-24	11143-11144	,	_
68-25	11145-11154	component	_
68-26	11155-11161	reward	_
68-27	11162-11172	subregions	_
68-28	11173-11174	,	_
68-29	11175-11178	and	_
68-30	11179-11189	comparison	_
68-31	11190-11197	regions	_
68-32	11198-11200	by	_
68-33	11201-11212	determining	_
68-34	11213-11224	percentages	_
68-35	11225-11227	of	_
68-36	11228-11232	each	_
68-37	11233-11239	region	_
68-38	11240-11248	relative	_
68-39	11249-11251	to	_
68-40	11252-11257	total	_
68-41	11258-11266	cerebral	_
68-42	11267-11273	volume	_
68-43	11274-11277	for	_
68-44	11278-11282	each	_
68-45	11283-11290	subject	_
68-46	11291-11292	.	_

69-1	11293-11295	Of	_
69-2	11296-11300	note	_
69-3	11301-11302	,	_
69-4	11303-11305	we	_
69-5	11306-11310	also	_
69-6	11311-11319	computed	_
69-7	11320-11329	analogous	_
69-8	11330-11338	regional	_
69-9	11339-11346	volumes	_
69-10	11347-11349	as	_
69-11	11350-11351	a	_
69-12	11352-11362	percentage	_
69-13	11363-11365	of	_
69-14	11366-11378	intracranial	_
69-15	11379-11385	volume	_
69-16	11386-11387	(	_
69-17	11388-11400	Supplemental	_
69-18	11401-11407	Tables	_
69-19	11408-11409	2	_
69-20	11410-11413	and	_
69-21	11414-11415	5	_
69-22	11416-11417	)	_
69-23	11418-11420	in	_
69-24	11421-11426	order	_
69-25	11427-11429	to	_
69-26	11430-11437	measure	_
69-27	11438-11441	the	_
69-28	11442-11452	subregions	_
69-29	11453-11461	relative	_
69-30	11462-11464	to	_
69-31	11465-11472	cranial	_
69-32	11473-11477	size	_
69-33	11478-11479	,	_
69-34	11480-11483	and	_
69-35	11484-11488	also	_
69-36	11489-11495	report	_
69-37	11496-11499	the	_
69-38	11500-11503	raw	_
69-39	11504-11512	regional	_
69-40	11513-11520	volumes	_
69-41	11521-11522	(	_
69-42	11523-11535	Supplemental	_
69-43	11536-11541	Table	_
69-44	11542-11543	3	_
69-45	11544-11545	)	_
69-46	11546-11547	.	_

70-1	11548-11551	The	_
70-2	11552-11559	results	_
70-3	11560-11562	of	_
70-4	11563-11566	the	_
70-5	11567-11570	raw	_
70-6	11571-11577	volume	_
70-7	11578-11586	analyses	_
70-8	11587-11591	were	_
70-9	11592-11599	similar	_
70-10	11600-11602	to	_
70-11	11603-11611	analyses	_
70-12	11612-11614	of	_
70-13	11615-11627	proportional	_
70-14	11628-11635	volumes	_
70-15	11636-11637	,	_
70-16	11638-11642	with	_
70-17	11643-11646	the	_
70-18	11647-11655	expected	_
70-19	11656-11665	exception	_
70-20	11666-11670	that	_
70-21	11671-11674	men	_
70-22	11675-11679	have	_
70-23	11680-11686	larger	_
70-24	11687-11692	heads	_
70-25	11693-11694	(	_
70-26	11695-11698	and	_
70-27	11699-11705	brains	_
70-28	11706-11707	)	_
70-29	11708-11712	than	_
70-30	11713-11718	women	_
70-31	11719-11720	.	_

71-1	11721-11723	We	_
71-2	11724-11731	applied	_
71-3	11732-11738	linear	_
71-4	11739-11749	regression	_
71-5	11750-11758	analyses	_
71-6	11759-11760	(	_
71-7	11761-11769	covaried	_
71-8	11770-11773	for	_
71-9	11774-11777	age	_
71-10	11778-11779	)	_
71-11	11780-11782	to	_
71-12	11783-11789	assess	_
71-13	11790-11793	the	_
71-14	11794-11807	relationships	_
71-15	11808-11815	between	_
71-16	11816-11822	global	_
71-17	11823-11826	and	_
71-18	11827-11833	reward	_
71-19	11834-11843	subregion	_
71-20	11844-11851	volumes	_
71-21	11852-11854	as	_
71-22	11855-11864	predicted	_
71-23	11865-11867	by	_
71-24	11868-11871	age	_
71-25	11872-11873	,	_
71-26	11874-11884	alcoholism	_
71-27	11885-11886	,	_
71-28	11887-11893	gender	_
71-29	11894-11895	,	_
71-30	11896-11899	and	_
71-31	11900-11903	the	_
71-32	11904-11914	alcoholism	_
71-33	11915-11917	by	_
71-34	11918-11924	gender	_
71-35	11925-11936	interaction	_
71-36	11937-11938	.	_

72-1	11939-11943	Then	_
72-2	11944-11945	,	_
72-3	11946-11951	among	_
72-4	11952-11962	alcoholics	_
72-5	11963-11968	alone	_
72-6	11969-11970	,	_
72-7	11971-11977	models	_
72-8	11978-11982	were	_
72-9	11983-11994	constructed	_
72-10	11995-11998	for	_
72-11	11999-12003	each	_
72-12	12004-12010	region	_
72-13	12011-12012	,	_
72-14	12013-12015	as	_
72-15	12016-12025	predicted	_
72-16	12026-12028	by	_
72-17	12029-12032	age	_
72-18	12033-12034	,	_
72-19	12035-12041	gender	_
72-20	12042-12043	,	_
72-21	12044-12052	drinking	_
72-22	12053-12060	history	_
72-23	12061-12062	(	_
72-24	12063-12067	i.e.	_
72-25	12068-12069	,	_
72-26	12070-12073	DHD	_
72-27	12074-12075	,	_
72-28	12076-12078	DD	_
72-29	12079-12080	,	_
72-30	12081-12083	or	_
72-31	12084-12087	LOS	_
72-32	12088-12089	)	_
72-33	12090-12091	,	_
72-34	12092-12095	and	_
72-35	12096-12099	the	_
72-36	12100-12111	interaction	_
72-37	12112-12114	of	_
72-38	12115-12119	each	_
72-39	12120-12128	drinking	_
72-40	12129-12136	history	_
72-41	12137-12144	measure	_
72-42	12145-12149	with	_
72-43	12150-12156	gender	_
72-44	12157-12158	.	_

73-1	12159-12164	Based	_
73-2	12165-12169	upon	_
73-3	12170-12171	a	_
73-4	12172-12183	discrepancy	_
73-5	12184-12186	in	_
73-6	12187-12190	the	_
73-7	12191-12201	literature	_
73-8	12202-12211	regarding	_
73-9	12212-12218	gender	_
73-10	12219-12230	differences	_
73-11	12231-12233	in	_
73-12	12234-12242	relation	_
73-13	12243-12245	to	_
73-14	12246-12264	alcoholism-related	_
73-15	12265-12270	brain	_
73-16	12271-12284	abnormalities	_
73-17	12285-12286	,	_
73-18	12287-12302	non-directional	_
73-19	12303-12314	statistical	_
73-20	12315-12325	procedures	_
73-21	12326-12327	(	_
73-22	12328-12332	i.e.	_
73-23	12333-12334	,	_
73-24	12335-12345	two-tailed	_
73-25	12346-12351	tests	_
73-26	12352-12353	)	_
73-27	12354-12358	were	_
73-28	12359-12368	necessary	_
73-29	12369-12373	when	_
73-30	12374-12383	examining	_
73-31	12384-12387	the	_
73-32	12388-12393	brain	_
73-33	12394-12401	volumes	_
73-34	12402-12404	of	_
73-35	12405-12413	interest	_
73-36	12414-12415	.	_

74-1	12416-12418	In	_
74-2	12419-12422	all	_
74-3	12423-12434	significant	_
74-4	12435-12446	statistical	_
74-5	12447-12455	analyses	_
74-6	12456-12457	,	_
74-7	12458-12461	the	_
74-8	12462-12466	data	_
74-9	12467-12471	from	_
74-10	12472-12484	participants	_
74-11	12485-12489	were	_
74-12	12490-12497	removed	_
74-13	12498-12500	if	_
74-14	12501-12505	Cook	_
74-15	12506-12508	's	_
74-16	12509-12510	D	_
74-17	12511-12519	exceeded	_
74-18	12520-12521	1	_
74-19	12522-12523	,	_
74-20	12524-12526	to	_
74-21	12527-12534	account	_
74-22	12535-12538	for	_
74-23	12539-12551	participants	_
74-24	12552-12556	with	_
74-25	12557-12573	disproportionate	_
74-26	12574-12583	influence	_
74-27	12584-12585	.	_

75-1	12586-12590	This	_
75-2	12591-12600	procedure	_
75-3	12601-12609	resulted	_
75-4	12610-12612	in	_
75-5	12613-12616	the	_
75-6	12617-12624	removal	_
75-7	12625-12627	of	_
75-8	12628-12631	one	_
75-9	12632-12635	ALC	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
75-10	12636-12641	woman	_
75-11	12642-12645	for	_
75-12	12646-12649	the	_
75-13	12650-12662	relationship	_
75-14	12663-12665	of	_
75-15	12666-12669	LOS	_
75-16	12670-12672	to	_
75-17	12673-12684	ventricular	_
75-18	12685-12691	volume	_
75-19	12692-12693	.	_

76-1	12694-12700	Direct	_
76-2	12701-12712	comparisons	_
76-3	12713-12719	within	_
76-4	12720-12729	subgroups	_
76-5	12730-12739	according	_
76-6	12740-12742	to	_
76-7	12743-12749	gender	_
76-8	12750-12751	(	_
76-9	12752-12755	men	_
76-10	12756-12759	vs.	_
76-11	12760-12765	women	_
76-12	12766-12767	)	_
76-13	12768-12771	and	_
76-14	12772-12777	group	_
76-15	12778-12779	(	_
76-16	12780-12783	ALC	_
76-17	12784-12787	vs.	_
76-18	12788-12790	NC	_
76-19	12791-12792	)	_
76-20	12793-12797	were	_
76-21	12798-12807	conducted	_
76-22	12808-12810	to	_
76-23	12811-12815	shed	_
76-24	12816-12821	light	_
76-25	12822-12824	on	_
76-26	12825-12828	the	_
76-27	12829-12836	results	_
76-28	12837-12839	of	_
76-29	12840-12851	significant	_
76-30	12852-12864	interactions	_
76-31	12865-12866	.	_

77-1	12867-12875	Likewise	_
77-2	12876-12877	,	_
77-3	12878-12886	analyses	_
77-4	12887-12889	of	_
77-5	12890-12898	drinking	_
77-6	12899-12908	variables	_
77-7	12909-12912	are	_
77-8	12913-12921	reported	_
77-9	12922-12928	within	_
77-10	12929-12932	the	_
77-11	12933-12939	gender	_
77-12	12940-12949	subgroups	_
77-13	12950-12951	.	_

